Dual Government in Catalonia? : Josep Goded


Pro-independence parties have restarted talks on the formation of an effective government in Catalonia. The negotiations broke down two weeks ago, following a wave of mutual reproaches and criticism. However, the announcement of the Spanish government that it will use its direct rule over Catalonia to eliminate Catalan as a vernacular language at schools has forced ERC and JxCat to understand each other and accelerate their negotiations.

A number of possible formulas to swear in Puigdemont as president are under discussion. The possibility of forming a dual government with some members in Brussels and others in Barcelona appears to be the most feasible one. In an interview with ACN (Catalan News Agency), Elsa Artadi (JxCat) said that her party and the ERC are preparing the necessary logistics to make it possible to govern from both places.

She also said that Puigdemont has to be sworn in even though the Spanish Constitutional Court and the Spanish government are determined to prevent it from happening. She explains that Puigdemont cannot be just a symbolic figure. For her candidacy, she has to “govern, be part of the executive power and have completelegitimacy.” Artadi added that Puigdemont should be the leader of the country, the one “setting the tone” of Catalonia’s politics.

 

Source: Dual Government in Catalonia? : Josep Goded

The Week that Spain Lost Catalonia


Has the Spanish Government scored an own goal, for no matter about the rights and wrongs, the legitimacy or not and the support for the Catalonia Independence referendum by the Spanish actions this could solidify support for the referendum which may or may not have been there originally.

To make matters even worse they instructed or the Spanish courts did to use excessive force to stop the referendum.

Courts do not usually create actions by themselves, but others have to make applications to them, was this the Spanish Government or one or more of their supporters. In bringing these many actions this may be increasing support for the Catalonian independence movement and be bringing it even closer to an affirmative conclusion.

Josep Goded

The detention of 15 high-ranking officials and the suspension of the Catalan government, last week by the Spanish government, in order to halt the referendum on independence set for tomorrow appears to have united separatists, federalists, and a significant number of unionists in defense of the vote.

“I have always been opposed to this referendum, because I am a federalist. However, the latest Spanish aggressions against Catalonia in order to humiliate our people is intolerable. That’s the main reason why I have decided to vote, and I will vote “YES” because I do not want to belong to a dictatorship like Turkey any longer. I think that the creation of a new state would give us the chance to build a more fair country and society” said David, a Barcelona citizen.

My family and I have always voted for unionist parties. We like Spain and most of our…

View original post 321 more words

Shire receives European approval for INTUNIV as a non-stimulant ADHD treatment for children and adolescents


Original post from Medical News Today

‘…………….

Shire has announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant INTUNIV® (guanfacine hydrochloride prolonged release tablets) for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.1 INTUNIV must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.1

“The approval of INTUNIV marks a significant advance in the treatment of ADHD in children and adolescents in Europe. Previously, physicians had only one licensed non-stimulant option for these patients,” said Perry Sternberg, Senior Vice President, Neuroscience Business Unit, Shire. “The importance of simply providing physicians with the ability to choose the non- stimulant option that may best suit the needs of their patients should not be overlooked, considering the complexities and different manifestations of the disorder in children and adolescents.”

The European Commission decision to grant approval is based on data from three pivotal Phase 3 studies investigating the short- and long-term safety and efficacy of INTUNIV in children and adolescents with ADHD.2-4

The European Commission decision to grant Marketing Authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) in July 2015 and applies to all 28 EU member states and Iceland, Liechtenstein and Norway.

About ADHD in children and adolescents

ADHD is a common psychiatric disorder in children and adolescents5-7and is recognised by the World Health Organization (WHO).8 The core symptoms are inattention, hyperactivity and impulsivity.7 Worldwide, prevalence of ADHD is estimated to be between 5.29% and 7.1%, and just under 5% for children and adolescents (<18 years).5,69-11

About INTUNIV

INTUNIV is indicated in the EU, Iceland, Liechtenstein and Norway as a non-stimulant for the treatment of ADHD in children and adolescents aged 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.1

INTUNIV must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.1

Guanfacine is a selective alpha-2A adrenergic receptor agonist in that it has 15-20 times higher affinity for this receptor subtype than for the alpha-2B or alpha-2C subtypes.1 Guanfacine is a non-stimulant. The mode of action of guanfacine in ADHD is not fully established. Preclinical research suggests guanfacine modulates signalling in the prefrontal cortex and basal ganglia through direct modification of synaptic noradrenalin transmission at the alpha 2- adrenergic receptors.1

The effects of guanfacine in the treatment of ADHD have been examined in children and adolescents (6 to 17 years). Guanfacine showed significantly greater efficacy than placebo on symptoms of ADHD based upon investigator ratings on the ADHD Rating Scale (ADHD-RS).1

INTUNIV is also licensed in the US and Canada. For more information on the product labelling in these markets, refer to the US Prescribing Information and the Canadian Product Monograph, respectively. In the US, generic versions of Intuniv for the treatment of ADHD are available.

Adapted by MNT from original media release

Read more breaking health news on our homepage

References

1. Intuniv Summary of Product Characteristics. Shire Pharmaceuticals Ireland Limited. 2015.

2. HERVAS A, et al. (2014) Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 24:1861-72.

3. NEWCORN JH, et al. (2014) Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): double-blind, placebo-controlled, multicentre, phase 3, randomized withdrawal study. Poster presented at the 22nd European Congress of Psychiatry; Munich, Germany.

4. WILENS TE, et al. (2014) A multicentre, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder. Poster presented at the 3rd EUNETHYDIS International Conference on ADHD; Istanbul, Turkey.

5. POLANCZYK G, et al. (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 164:942-8.

6. WILLCUTT EG. (2012) The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics.   ………..